crispr
therapy
severe
hemoglobinopathies
accepted
plenary
presentation
american
society
hematology
ash
meeting
exposition
zug
switzerland
cambridge
mass
boston
globe
newswire
crispr
therapeutics
nasdaq
crsp
vertex
pharmaceuticals
incorporated
nasdaq
vrtx
today
announced
data
seven
patients
two
ongoing
phase
clinical
trials
investigational
crispr
therapy
severe
hemoglobinopathies
accepted
oral
presentation
plenary
scientific
session
annual
ash
meeting
exposition
take
place
virtually
december
haydar
frangoul
medical
director
pediatric
hematology
oncology
sarah
cannon
research
institute
hca
healthcare
tristar
centennial
medical
center
deliver
presentation
behalf
authors
december
abstract
posted
online
today
includes
data
five
patients
three
months
months
infusion
ongoing
phase
trial
beta
thalassemia
tdt
data
two
patients
three
months
months
ongoing
phase
trial
severe
sickle
cell
disease
scd
additional
data
presented
ash
including
data
patients
included
abstract
data
additional
patients
greater
three
months
investigated
two
ongoing
clinical
trials
potential
curative
therapy
patients
suffering
tdt
severe
scd
accepted
abstract
available
ash
conference
website
investigational
autologous
ex
vivo
crispr
therapy
evaluated
patients
suffering
tdt
severe
scd
patient
hematopoietic
stem
cells
engineered
produce
high
levels
fetal
hemoglobin
hbf
hemoglobin
f
red
blood
cells
hbf
form
hemoglobin
naturally
present
birth
switches
adult
form
hemoglobin
elevation
hbf
potential
alleviate
transfusion
requirements
tdt
patients
reduce
painful
debilitating
sickle
crises
scd
patients
based
progress
program
date
granted
regenerative
medicine
advanced
therapy
rmat
fast
track
orphan
drug
rare
pediatric
disease
designations
food
drug
administration
fda
also
granted
orphan
drug
designation
european
commission
tdt
scd
well
priority
medicines
prime
designation
european
medicines
agency
ema
scd
developed
agreement
crispr
therapeutics
vertex
among
approaches
investigated
evaluated
tdt
scd
furthest
advanced
clinical
development
ongoing
phase
trial
designed
assess
safety
efficacy
single
dose
patients
ages
tdt
trial
enroll
patients
follow
patients
approximately
two
years
infusion
patient
asked
participate
trial
ongoing
phase
trial
designed
assess
safety
efficacy
single
dose
patients
ages
severe
scd
trial
enroll
patients
follow
patients
approximately
two
years
infusion
patient
asked
participate
trial
process
trials
patients
enroll
trials
hematopoietic
stem
progenitor
cells
collected
peripheral
blood
patient
cells
edited
using
crispr
technology
edited
cells
infused
back
patient
part
stem
cell
transplant
process
involves
among
things
patient
treated
myeloablative
busulfan
conditioning
patients
undergoing
stem
cell
transplants
may
also
encounter
side
effects
ranging
mild
severe
unrelated
administration
patients
initially
monitored
determine
edited
cells
begin
produce
mature
blood
cells
process
known
engraftment
engraftment
patients
continue
monitored
track
impact
multiple
measures
disease
safety
collaboration
crispr
therapeutics
vertex
entered
strategic
research
collaboration
focused
use
crispr
discover
develop
potential
new
treatments
aimed
underlying
genetic
causes
human
disease
represents
first
potential
treatment
emerge
joint
research
program
crispr
therapeutics
vertex
jointly
develop
commercialize
equally
share
research
development
costs
profits
worldwide
crispr
therapeutics
crispr
therapeutics
leading
gene
editing
company
focused
developing
transformative
medicines
serious
diseases
using
proprietary
crispr
platform
crispr
revolutionary
gene
editing
technology
allows
precise
directed
changes
genomic
dna
crispr
therapeutics
established
portfolio
therapeutic
programs
across
broad
range
disease
areas
including
hemoglobinopathies
oncology
regenerative
medicine
rare
diseases
accelerate
expand
efforts
crispr
therapeutics
established
strategic
collaborations
leading
companies
including
bayer
vertex
pharmaceuticals
viacyte
crispr
therapeutics
ag
headquartered
zug
switzerland
subsidiary
crispr
therapeutics
r
operations
based
cambridge
massachusetts
business
offices
san
francisco
california
london
united
kingdom
information
please
visit
crispr
therapeutics
statement
press
release
may
contain
number
statements
within
meaning
private
securities
litigation
reform
act
amended
well
statements
regarding
crispr
therapeutics
expectations
following
status
clinical
trials
including
without
limitation
expected
timing
data
releases
related
product
candidates
development
crispr
therapeutics
collaborators
including
expectations
regarding
data
plans
present
data
annual
ash
meeting
exposition
ii
expected
benefits
crispr
therapeutics
collaborations
iii
therapeutic
value
development
commercial
potential
crispr
gene
editing
technologies
therapies
without
limiting
foregoing
words
believes
anticipates
plans
expects
similar
expressions
intended
identify
statements
cautioned
statements
inherently
uncertain
although
crispr
therapeutics
believes
statements
based
reasonable
assumptions
within
bounds
knowledge
business
operations
statements
neither
promises
guarantees
necessarily
subject
high
degree
uncertainty
risk
actual
performance
results
may
differ
materially
projected
suggested
statements
due
various
risks
uncertainties
risks
uncertainties
include
among
others
potential
initial
preliminary
data
clinical
trial
initial
data
limited
number
patients
case
time
indicative
final
trial
results
potential
clinical
trial
results
may
favorable
potential
impacts
due
coronavirus
pandemic
timing
progress
clinical
trials
future
competitive
market
factors
may
adversely
affect
commercial
potential
uncertainties
regarding
intellectual
property
protection
crispr
therapeutics
technology
intellectual
property
belonging
third
parties
outcome
proceedings
interference
opposition
similar
proceeding
involving
portion
intellectual
property
risks
uncertainties
described
heading
risk
factors
crispr
therapeutics
recent
annual
report
form
quarterly
report
form
subsequent
filings
made
crispr
therapeutics
securities
exchange
commission
available
sec
website
existing
prospective
investors
cautioned
place
undue
reliance
statements
speak
date
made
crispr
therapeutics
disclaims
obligation
undertaking
update
revise
statements
contained
press
release
extent
required
law
crispr
word
mark
design
logo
trademarks
registered
trademarks
crispr
therapeutics
ag
trademarks
registered
trademarks
property
respective
owners
vertex
vertex
global
biotechnology
company
invests
scientific
innovation
create
transformative
medicines
people
serious
diseases
company
multiple
approved
medicines
treat
underlying
cause
cystic
fibrosis
cf
rare
genetic
disease
several
ongoing
clinical
research
programs
cf
beyond
cf
vertex
robust
pipeline
investigational
small
molecule
medicines
serious
diseases
deep
insight
causal
human
biology
including
pain
antitrypsin
deficiency
kidney
diseases
addition
vertex
rapidly
expanding
pipeline
genetic
cell
therapies
diseases
sickle
cell
disease
beta
thalassemia
duchenne
muscular
dystrophy
type
diabetes
mellitus
founded
cambridge
vertex
global
headquarters
located
boston
innovation
district
international
headquarters
london
additionally
company
research
development
sites
commercial
offices
north
america
europe
australia
latin
america
vertex
consistently
recognized
one
industry
top
places
work
including
consecutive
years
science
magazine
top
employers
list
best
place
work
lgbtq
equality
human
rights
campaign
company
updates
learn
vertex
history
innovation
visit
follow
us
facebook
twitter
linkedin
youtube
instagram
vertex
special
note
regarding
statements
press
release
contains
statements
defined
private
securities
litigation
reform
act
including
without
limitation
statements
regarding
expectations
plans
present
data
annual
ash
meeting
exposition
development
including
expected
timeline
development
potential
benefits
plans
expectations
clinical
trials
clinical
trial
sites
status
clinical
trials
product
candidates
development
us
collaborators
including
activities
clinical
trial
sites
potential
outcomes
vertex
believes
statements
contained
press
release
accurate
statements
represent
company
beliefs
date
press
release
number
risks
uncertainties
could
cause
actual
events
results
differ
materially
expressed
implied
statements
risks
uncertainties
include
among
things
data
company
development
programs
including
programs
collaborators
may
support
registration
development
compounds
due
safety
efficacy
reasons
risks
listed
risk
factors
vertex
recent
annual
report
subsequent
quarterly
reports
filed
securities
exchange
commission
available
company
website
place
undue
reliance
statements
scientific
data
presented
vertex
disclaims
obligation
update
information
contained
press
release
new
information
becomes
available
crispr
therapeutics
investor
contact
susan
kim
crispr
therapeutics
media
contact
rachel
eides
wcg
behalf
crispr
reides
vertex
pharmaceuticals
incorporated
investors
michael
partridge
zach
barber
brenda
eustace
media
mediainfo
heather
nichols
international
